Drug Approval | May 05, 2026
Lupin receives USFDA approval for generic Ravicti oral liquid
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Under the new policy, financial assistance has been increased to Rs 50 lakh per patient to improve treatment access
Discussions focused on digital health, non-communicable diseases, resilient supply chains, medical innovation, and healthcare workforce development
The ISG assessment highlights Indegene’s deep domain expertise, proprietary technology stack, and expanding use of AI and GenAI to drive more integrated, data-led commercial execution across the life sciences value chain
The conference brought together over 500 doctors and 150 nutritionists to discuss emerging obesity-related challenges
The private funding rose 38% amid growing international collaborations and CDMO demand
The latest addition, a new API facility in Morrisville, North Carolina, will produce key components for solid dosage tablets, capsules, and RNA therapeutics
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Report highlights growing confidence in digitalisation and AI, even as healthcare leaders remain concerned about workforce gaps, cybersecurity, and data readiness
Leadership transition strengthens Redcliffe Labs’ focus on scaling technology-led diagnostics, operational excellence, and preventive healthcare access
Subscribe To Our Newsletter & Stay Updated
